Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed $16.5B acquisition of Catalent (CTLT), Reuters’ Foo Yun Chee and Maggie Fick report, citing a person with direct knowledge of the matter. Another source told Reuters that Catalent is preparing senior management for the takeover to go through.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk’s Ambitious Share Buyback Initiative
- Novo Nordisk Executives Purchase ADRs on NYSE
- Novo Nordisk Executives Engage in Share Transactions
- Novo Nordisk placed on ‘Positive Catalyst Watch’ at JPMorgan
- Novo Nordisk Executives Sell Shares Worth DKK 4.74 Billion
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
